biomedicina slovenica


"FIBRINOLYSIS" : 227

  1. Hrovat Katja; Rehberger Likozar Andreja; Zupan Janja; Šebeštjen Miran
    Gene expression profiling of markers of inflammation, angiogenesis, coagulation and fibrinolysis in patients with coronary artery disease with very high lipoprotein(a) levels treated with PCSK9 inhibitors
    2022
  2. Ugovšek Sabina; Šebeštjen Miran
    Lipoprotein(a)—the crossroads of atherosclerosis, atherothrombosis and inflammation
    2022
  3. Shanmugasundaram Madhan; Truong Huu Tam; Harash Ahmed; Hu David; Tran Arielle; Smith Nicole; Ciurlino Brian; Noč Marko; Hsu Paul; Kern Karl B.
    Extending time to reperfusion with mild therapeutic hypothermia
    2021
  4. Faganel Barbara; Strandberg Karin; Debeljak Maruša; Kitanovski Lidija; Jazbec Janez; Benedik-Dolničar Majda; Trampuš-Bakija Alenka
    Von Willebrand factor alloantibodies in type 3 von Willebrand disease
    2020
  5. Poredoš Pavel; Poredoš Peter; Ježovnik Mateja
    Heparin promotes recanalization of venous thrombotic occlusions
    2018
  6. Rakuša Matej; Jensterle Sever Mojca; Božič Mojca; Janež Andrej
    Increased coagulation and decreased fibrinolysis as measured with overall hemostatic potential are dependent on BMI and not associated with PCOS
    2017
  7. Final programme
    2008
  8. Marinšek Martin; Sinkovič Andreja
    Ramipril and losartan exert a similar long-term effect upon markers of heart failure, endogenous fibrinolysis, and platelet aggregation in survivors of ST-elevation myocardial infarction
    2016
  9. Medvešček Marko; Keber Dušan; Stegnar Mojca
    Impaired fibrinolysis in offsprings of parental pairs with type-2 diabetes-mellitus
    1995
  10. Naji Franjo; Kanič Vojko
    Temelji antikoagulantnega zdravljenj[a]
    2007
  11. Žegura Branka; Gužič-Salobir Barbara; Šebeštjen Miran; Keber Irena
    Various menopausal hormone therapies and markers of inflammation, coagulation, fibrinolysis, lipids and lipoproteins in healthy postmenopausal women
    2008
  12. Ježovnik Mateja; Poredoš Pavel
    Factors influencing the recanalisation rate of deep venous thrombosis
    2012
  13. Meyer Guy; Kozak Matija
    Fibrinolysis for patients with intermediate-risk pulmonary embolism
    2014
  14. Eržen Barbara; Šabovič Mišo
    In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction
    2013
  15. Kalan Gorazd; Melkič Enver; Grošelj-Grenc Mojca
    Thromboelastometry in neonates and infants undergoing cardiac surgery
    2013
  16. Lovrečić Luca; Ristić Smiljana; Starčević-Čizmarević Nada; Brajenović-Milić Bojana; Šega-Jazbec Saša; Sepčić Juraj; Kapović Miljenko; Peterlin Borut
    PAI and TPA gene polymorphisms in multiple sclerosis
    2008
  17. Sinkovič Andreja
    Bolnik z akutnim miokardnim infarktom - ukrepi ob akutnem dogodku in ukrepanje v bolnišnici
    2010
  18. Preložnik-Zupan Irena; Šabovič Miso; Salobir Barbara; Buturović-Ponikvar Jadranka
    Characterization of the pro-thrombotic state in CAPD patients
    2008
  19. Štupnik Tomaž; Vidmar Stanko; Eržen Janez; Sok Mihael
    Intraplevralna uporaba streptokinaze
    [Intrapleural use of streptokinase]
    2008
  20. Salobir Barbara; Šabovič Mišo; Preložnik-Zupan Irena; Buturović-Ponikvar Jadranka
    Platelet (dys)function and plasma plasminogen levels in hemodialysis patients
    2008
  21. Anžej Saša; Božič Mojca; Antovič Aleksandra; Peternel Polona; Gašperšič Nataša; Rot Uroš; Tratar Gregor; Stegnar Mojca
    Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia
    2007
  22. Žegura Branka
    Različne oblike hormonskega nadomestnega zdravljenja po menopavzi in dejavniki tveganja za aterosklerozo
    2007
  23. Juhan-Vague I; Alessi MC; Mavri A; Morange PE
    Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
    2003
  24. Bastelica D; Mavri A; Verdierl M; Berthet B; Juhan-Vague I; Alessi MC
    Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNFalpha receptors to PAI-1 levels
    2002
  25. Mavri A; Alessi MC; Juhan-Vague I
    Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases
    2004
  26. Urlep-Šalinović Vera; Krajnc Olga
    Metabolični sindrom, protrombotično stanje in trombofilije pri otrocih
    [Metabolic syndrome, prothrombotic state and thrombophilia in children]
    2007
  27. Fras Zlatko
    Vzroki povečanja fibrinolitične aktivnosti krvi med telesno aktivnostjo in farmakološkim spodbujanjem
    2007
  28. Stegnar Mojca; Vižintin-Cuderman Tjaša; Božič Mojca
    Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability
    2007
  29. Pakiž Maja
    Občutljivost trombembolov iz pljučne arterije na zunajtelesno trombolizo
    2006
  30. Mavri Alenka
    Stalnost fibrinolitičnega odgovora na venski zažem pri zdravih
    1992
  31. Toff William D; Jones Chris I; Ford Isobel; Pearse Robert J; Watson Henry G; Watt Stephen J; Ross John AS; Gradwell David P; Batchelor Antony J; Abrams Keith R
    Učinek hipobarične hipoksije, ki posnema stanja med dolgotrajnim letalskim poletom, na koagulacijo, fibrinolizo, funkcijo trombocitov in endotelijsko aktivacijo
    [Effect of hypobaric hypoxia, simulating conditions during long-haul air travel, on coagulation, fibrinolysis, platelet function, and endothelial activation]
    2006
  32. Šabovič Mišo; Salobir Barbara; Preložnik-Zupan Irena; Bratina Petra; Bojec Vida; Buturović-Ponikvar Jadranka
    The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis
    2005
  33. Žegura Branka; Gužič-Salobir Barbara; Šebeštjen Miran; Keber Irena
    The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women
    2006
  34. Štepec Srečko
    Motnje v nastajanju in strjevanju krvi pri jetrnih boleznih
    2006
  35. Žegura Branka; Guzič-Salobir B; Šebeštjen M; Keber I
    The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids and lipoproteins in healthy postmenopausal women
    2006
  36. Joras M; Poredoš P; Fras Z
    Endothelial dysfunction in Buerger's disease and its relation to markers of inflammation
    2006
  37. Stecher Adela; Kremžar Boriana
    Mehanizem delovanja rekombinantnega faktorja VIIa in uporaba pri stanjih, ki jih spremlja huda krvavitev
    [Mode of action of recombinant factor VIIa and the use in severe haemorrhage states]
    2006
  38. Stegnar Mojca
    Prepoznavanje motenj hemostaze z laboratorijskimi metodami
    2005
  39. Sinkovič A; Pehnec Z
    In-hospital mortality and treatment in elderly patients with ST-elevation myocardial infarction
    2005
  40. Keber D; Kloboves V
    No net relase of t-PA and PAI-1 antigen from the pulmonary vascular bed
    1992
  41. Šabovič Mišo; Ključevšek Tomaž
    Resolution of Budd-Chiari syndrome due to activation of endogenous fibrinolysis that may be induced by weight reduction
    2005
  42. Mavri Alenka
    Povezava med metabolnim sindromom, inhibitorjem aktivatorja plazminogena (PAI-1) in aterosklerozo
    [Metabolic syndrome, plasminogen activator inhibitor (PAI-1) and atherosclerosis]
    2005
  43. Šebeštjen Miran
    Novi dejavniki tveganja za aterosklerozo: pomen in možnosti zdravljenja
    2005
  44. Preložnik-Zupan Irena
    Pomen ocene hemostaze z zapiralnim časom in pomanjkanja železa z deležem hipokromnih eritrocitov ter povezanost obeh pri kroničnih dializnih bolnikih
    2005
  45. Fras Zlatko; Keber Dušan; Chandler Wayne L
    The effect of submaximal exercise on fibrinolysis
    2004
  46. Urlep-Šalinović Vera
    Laboratorijska diagnostika hemostatskih motenj v porodništvu
    2004
  47. Stegnar Mojca; Vene Nina; Božič Mojca
    Do haemostasis activation markers that predict cardiovascular disease exist?
    2004
  48. Peternel Luka; Stegnar Mojca
    Hemostaza pri glodalcih - povezava s predkliničnimi raziskavami novih antitrombotikov
    [Hemostasis in rodents - an association with preclinical studies of novel antithrombotics]
    2004
  49. Šabovič Mišo; Kloboves-Prevodnik Veronika; Keber Dušan
    Comparison of fibrinolytic activity in the femoral vein and the right atrium
    2004
  50. Kloboves-Prevodnik Veronika; Šabovič Mišo; Keber Dušan
    Effect of blood passage through the pulmonary circulation on fibrinolytic parameters
    2004
  51. Žvan Bojana
    Razvrstitev, epidemiologija, diagnostika in zdravljenje možganskožilnih bolezni
    2004
  52. Salobir Barbara; Šabovič Mišo
    Possible vascular-bed-specific role of interleukin-6 in young women with a history of myocardial infarction, lacunar cerebral infarction and deep vein thrombosis
    2004
  53. Šabovič Mišo; Lavre Simona; Keber Irena
    Supplementation of wheat fibre can improve risk profile in patients with dysmetabolic cardiovascular syndrome
    2004
  54. Reiner Željko; Tedeschi-Reiner Eugenia
    Vloga statinov v preprečevanju srčno-žilnih bolezni
    [The role of statins in the prevention of cardiovascular diseases]
    2002
  55. Meško-Brguljan Pika; Turk Vito; Cimerman Nina; Brzin Jože; Križaj Igor; Popovič Tatjana
    Breakdown of neuropeptides by human brain cathepsin H
    2004
  56. Cimerman Nina; Košnik Mitja; Kern Izidor; Kos Janko; Meško-Brguljan Pika
    Cystatin C, inhibitor of cysteine proteinases, in asthma
    2004
  57. Anonymous ;
    ISFP. Abstracts of the 17th international congress on fibrinolysis and proteolysis; 2004 Mar 21-25; Melbourne
    2004
  58. Salobir B; Šabovič M; Peternel P; Stegnar M
    Vascular bed specific alterations in coagulation and fibrinolytic parameters in young women following myocardial infarction, lacunar cerebral infarction and deep vein thrombosis
    2003
  59. Ocepek Andreja; Skok Pavel
    Recidivne venske tromboze pri bolnici z ulceroznim kolitisom
    [Recurrent venous thrombosis in a patient with ulcerative colitis]
    2003
  60. Lokar L; Urlep-Šalinović V
    D-dimer pri diagnostiki venskih tromboembolij
    2003
  61. Shah PK; Kaul S; Nilsson J; Čerček B
    Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming. Part I
    2001
  62. Žegura Branka; Keber Irena; Šebeštjen Miran; Borko Elko; Koenig Wolfgang
    Vpliv nadomeščanja estradiola na označevalce vnetja, koagulacijo in fibrinolizo
    [The influence of estradiol replacement therapy in markers of inflammation, coagulation and fibrinolysis]
    2003
  63. Žegura Branka; Keber Irena; Šebeštjen Miran; Koenig Wolfgang
    Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis
    2003
  64. Salobir-Pajnič Barbara; Stegnar Mojca; Peternel Polona; Obersnel-Kveder Dunja; Grobovšek-Opara Sonja
    Fibrinolysis after myocardial infarction and venous thrombembolism in women in the reproductive period
    1995
  65. Salobir-Pajnič B; Hojnik M; Rozman B; Peternel P; Stegnar M
    Anticardiolipin antibodies are associated with monocytes, metabolic and fibrinolytic parameters in young women with a history of myocardial infarction
    1998
  66. Osredkar Joško
    Stopenjska laboratorijska diagnostika kardiovaskularnih bolezni
    [Stes in laboratory diagnostic of cardiovascular diseases]
    2003
  67. Blinc A; Magdič J; Fric J; Muševič I
    Atomic force microscopy of fibrin networks and plasma clots during fibrinolysis
    2000
  68. Pavelić Jasminka
    Molekularno-genetska osnova patogeneze sepse
    2003
  69. Kanič Vojko
    Metabolični sindrom
    [Metabolic syndrome]
    2003
  70. Šabovič Mišo; Kržišnik-Zorman Simona
    Plasminogen activator inhibitor-1, which is released from blood product transfusions, might be associated with (sub)acute thrombosis after coronary dilatation and stenting: a case report
    2003
  71. Mayhew Terry M
    Fibrin-type firbinoid in human placenta: a stereological analysis of its association with intervillous volume and villous surface area
    2001
  72. Breznik M; Pečar S
    Trombinski inhibitorji
    [Thrombin inhibitors]
    1997
  73. Benedik-Dolničar Majda
    Dozorevanje hemostaze v otroškem obdobju
    2002
  74. Gužič-Salobir Barbara; Keber Irena; Vrabič Lucija
    A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women
    2002
  75. Salobir Barbara
    Pomen neklasičnih dejavnikov tveganja za trombozo pri mladih ženskah s srčnim infarktom, cerebrovaskularnim inzultom in globoko vensko trombozo
    2002
  76. Špec-Marn Ana
    Pomen koagulcije v razvoju MOF-a
    2002
  77. Osredkar Joško
    Kardiovaskularna obolenja - laboratorijska diagnostika
    [Cardiovascular diseases - laboratory diagnostics]
    2002
  78. Kržišnik-Zorman Simona; Noč Marko
    Patofiziologija in klinična slika pri pljučni emboliji
    2002
  79. Sinkovič A
    Plasminogen activator inhibitor-1 in patients with atrial arrhythmias during acute myocardial infarction, treated with streptokinase
    2002
  80. Žegura B; Šebeštjen M; Keber I; Borko E; Koenig W
    The influence of estradiol replacement therapy (E2 RT) on markers of inflammation, coagulation and fibrinolysis
    2002
  81. Gužič-Salobir Barbara
    Dejavniki tveganja za aterosklerozo pri hormonskem nadomestnem zdravljenju v pomenopavzi
    2002
  82. Salobir Barbara; Šabovič Mišo; Peternel Polona; Stegnar Mojca
    Fibrinolytic parameters and lipoprotein(a) in young women with myocardial infarction
    2002
  83. Mavri Alenka
    Uravnavanje fibrinolitične aktivnosti krvi: vloga maščevja
    2001
  84. Šabovič Mirza
    Vpliv ACE-inhibitorjev na fibrinolitičen sistem: morebitna klinično pomembna "intrinzična" lastnost ACE-inhibitorjev
    2002
  85. Lavre Simona
    Učinki pšeničnih vlaken v prehrani pri bolnikih z metabolnim kardiovaskularnim sindromom
    2001
  86. Stegnar Mojca
    Disturbances of hemostasis in diabetes mellitus contributing to the development of atherosclerosis
    2001
  87. Stecher Adela
    Testi hemostaze
    2001
  88. Šurlan Miloš
    Endovaskularno zdravljenje žilnih bolezni
    2000
  89. Felez J
    Cell surface associated fibrinolysis
    2001
  90. Blinc A
    Transport of fibrinolytic agents as a rate-limiting step in fibrinolysis and thrombolysis
    2001
  91. Lijnen HR
    Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems
    2001
  92. Juhan-Vague I; Alessi MC; Morange PE
    Hypofibrinolysis and increased PAI-I are linked to atherothrombosis via insulin resistance and obesity
    2001
  93. Iacoviello L; Donati MB
    Gene-environment interactions: the example of coagulation factors
    2001
  94. Wiman B
    Fibrinolytic factors in connection with cardiovascular disease
    2001
  95. Gaffney PJ
    Fibrin degradation products. A review of structures found in vitro and in vivo
    2001
  96. Kluft C
    Standardization of fibrinolysis methods
    2001
  97. Grad Anton
    Vpliv sladkorne bolezni na možganskožilne bolezni
    [The impact of diabetes mellitus on cerebrovascular disorders]
    2001
  98. Kanič Vojko
    Sindrom X
    [Syndrome X]
    2001
  99. Poredoš Pavel
    Etiopatogeneza ateroskleroze
    [Pathogenesis of atherosclerosis]
    2001
  100. Mavri Alenka; Gužič-Salobir Barbara; Salobir-Pajnič Barbara; Keber Irena; Stare Janez; Stegnar Mojca
    Seasonal variation of some metabolic and haemostatic risk factors in subjects with and without coronary artery disease
    2001

1 101 201  



New search      Comments      Top of page Institute for Biostatistics and Medical Informatics